JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2008) 196, 57-65    DOI: 10.1677/JOE-07-0387
© 2008 Society for Endocrinology

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, H.
Right arrow Articles by Dear, A. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, H.
Right arrow Articles by Dear, A. E

Glucagon-like peptide-1 attenuates tumour necrosis factor-{alpha}-mediated induction of plasmogen activator inhibitor-1 expression

Hongbin Liu1,2, Yunshan Hu1,2, Richard W Simpson2,3 and Anthony E Dear1,2

1 Australian Centre for Blood Diseases and 2 Eastern Clinical Research Unit, Biotechnology Division, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia 3 Department of Diabetes and Endocrinology, 4th Floor Clive Ward Centre, Box Hill Hospital, Arnold Street, Box Hill 3128, Melbourne, Victoria, Australia

(Correspondence should be addressed to A E Dear; Email: anthony.dear{at}med.monash.edu.au)

Glucagon-like peptide-1 (GLP-1) has been proposed as a target for treatment of type 2 diabetes. GLP-1 has also been demonstrated to improve endothelial cell dysfunction in diabetic patients. Elevated plasmogen activator inhibitor-1 (PAI-1) levels have been implicated in endothelial cell dysfunction. The effect of GLP-1 on PAI-1 expression in vascular endothelial cells has not been explored. In a spontaneously transformed human umbilical vein endothelial cell (HUVEC) line, C11-spontaneously transformed HUVEC (STH) and primary HUVEC cells, GLP-1 treatment, in the presence of a dipeptidyl peptidase IV inhibitor, attenuated induction of PAI-1 protein and mRNA expression by tumour necrosis factor-{alpha} (TNF-{alpha}). GLP-1 also inhibited the effect of TNF-{alpha} on a reporter gene construct harbouring the proximal PAI-1 promoter. In addition, GLP-1 attenuated TNF-{alpha}-mediated induction of Nur77 mRNA and TNF-{alpha}-mediated binding of nuclear proteins (NPs) to the PAI-1, Nur77, cis-acting response element nerve growth factor induced clone B response element (NBRE). GLP-1 treatment also inhibited TNF-{alpha}-mediated induction of Akt phosphorylation. Taken together, these observations suggest that GLP-1 inhibits TNF-{alpha}-mediated PAI-1 induction in vascular endothelial cells, and this effect may involve Akt-mediated signalling events and the modulation of Nur77 expression and NP binding to the PAI-1 NBRE.







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Endocrinology.